Very Low Density Lipoprotein (VLDL), Human Plasma | MyBioSource MBS173148 product information

product summary

company name :

MyBioSource

product type :

protein

product name :

Very Low Density Lipoprotein (VLDL), Human Plasma

catalog :

MBS173148

quantity :

10 mg

price :

175 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS173148

products type :

Protein

products full name :

Very Low Density Lipoprotein (VLDL), Human Plasma

products short name :

Very Low Density Lipoprotein

products name syn :

Very Low Density Lipoprotein (VLDL)

other names :

very low-density lipoprotein receptor isoform a; Very low-density lipoprotein receptor; very low-density lipoprotein receptor; VLDL-R; VLDL receptor; very low density lipoprotein receptor

products gene name :

VLDL

other gene names :

VLDLR; VLDLR; CARMQ1; CHRMQ1; VLDLRCH; VLDL receptor; VLDL-R

uniprot entry name :

VLDLR_HUMAN

sequence length :

873

form :

Liquid

storage stability :

At -20 degree C

other info1 :

Source: Human Plasma. UNSPSC Code: 51131909. Total Cholesterol: 9,000 - 12,000 mg/dL

other info2 :

Recertification: 1 year

products categories :

Proteins; Antigens; Standards/controls; Native Proteins; Very Low Density Lipoprotein (vldl)

products description :

Custom preparations, technical support, bulk quantities and aliquoting available. Procedure: Ultracentrifugation performed to isolate Human Very Low Density lipoprotein (VLDL). Very Low Density Lipoprotein levels have been correlated with accelerated rates of atherosclerosis, and are elevated in a number of diseases and metabolic states. Human VLDL Inhibits DNA synthesis in lymphocytes activated by the nonspecific mitogen concanavalin A (Con A). Human VLDL are the next step down from chylomicrons in terms of size and lipid content. It transports endogenous triglycerides, phospholipids, cholesterol and cholesteryl esters. This functions as the body's internal transport mechanism for lipids. VLDL is defined as the lipoprotein fraction with the density range of 0.93 to 1.006 g/mL. It is spherical particle and in normal individuals ranges 30 to 80 nm in diameter. The molecular weight is 10 to 8 107. Compare with LDL particles, VLDL particles are heterogeneous in size and composition. VLDL particles can be separated in Sf 20-60 and Sf60-400. VLDL consists of protein 10%, phospholipid 19%, free cholesterol 7%, cholesterol ester 10% and triglycerides 56%. Apolipoprotein contribution% apoB 37 apoC 50 apoE 13 Apo B-48 is the sole constituent apolipoprotein on VLDL. It is presumed that the cholesteryl esters and triglycerides form the hydrophobic core, which is surrounded by a surface coat of apolipoprotein B, free cholesterol and polar phospholipid components oriented toward the aqueous medium.

ncbi gi num :

65301167

ncbi acc num :

NP_003374.3

ncbi gb acc num :

NM_003383.3

ncbi mol weight :

93,383 Da

ncbi pathways :

Lissencephaly Gene (LIS1) In Neuronal Migration And Development Pathway (137984); Reelin Signaling Pathway (137980)

ncbi summary :

The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. This gene encodes a lipoprotein receptor that is a member of the LDLR family and plays important roles in VLDL-triglyceride metabolism and the reelin signaling pathway. Mutations in this gene cause VLDLR-associated cerebellar hypoplasia. Alternative splicing generates multiple transcript variants encoding distinct isoforms for this gene. [provided by RefSeq, Aug 2009]

uniprot summary :

VLDLR: Binds VLDL and transports it into cells by endocytosis. In order to be internalized, the receptor-ligand complexes must first cluster into clathrin-coated pits. Binding to Reelin induces tyrosine phosphorylation of Dab1 and modulation of Tau phosphorylation. Defects in VLDLR are the cause of cerebellar ataxia mental retardation and dysequilibrium syndrome type 1 (CMARQ1); also known as dysequilibrium syndrome (DES) or non- progressive cerebellar disorder with mental retardation. CMARQ1 is a congenital, non-progressive cerebellar ataxia associated with disturbed equilibrium, delayed ambulation, mental retardation and cerebellar hypoplasia. Additional features include short stature, strabismus, pes planus and, rarely, seizures. 2 isoforms of the human protein are produced by alternative splicing. Protein type: Membrane protein, integral; Receptor, misc. Chromosomal Location of Human Ortholog: 9p24. Cellular Component: membrane; integral to membrane; plasma membrane; coated pit; receptor complex. Molecular Function: very-low-density lipoprotein receptor activity; low-density lipoprotein receptor activity; very-low-density lipoprotein binding; protein binding; apolipoprotein binding; calcium ion binding; glycoprotein binding; calcium-dependent protein binding. Biological Process: cholesterol metabolic process; nervous system development; receptor-mediated endocytosis; positive regulation of protein kinase activity; ventral spinal cord development; negative regulation of transcription from RNA polymerase II promoter; lipid transport; signal transduction; memory. Disease: Cerebellar Ataxia, Mental Retardation, And Dysequilibrium Syndrome 1

size1 :

10 mg

price1 :

175 USD

size2 :

100 mg

price2 :

300

size3 :

1 g

price3 :

1010

more info or order :

MyBioSource product webpage